NF-κB in type 1 diabetes.

Inflamm Allergy Drug Targets

St Vincent's Institute, 41 Victoria Parade, Fitzroy, Victoria 3065, Melbourne, Australia.

Published: June 2011

Type 1 diabetes is an autoimmune disease in which pancreatic beta cells are destroyed by autoreactive T cells. It is a common pediatric disease with increasing incidence. Islet transplantation may be a therapeutic option, however, the current limitations of this procedure mean that for most sufferers of type 1 diabetes there is no cure. The transcription factor NF-κB has been widely studied for its role in development of type 1 diabetes. Recent data have shown that NF-κB is required for activation of autoreactive T cells, and its hyperactivity in monocytes and dendritic cells results in altered cytokine secretion and antigen presentation, which ultimately contributes to the initiation of type 1 diabetes. NF-κB is also activated by a number of proinflammatory cytokines to regulate both the survival and death of beta cells. The critical role of NF-κB in type 1 diabetes renders it a promising pharmaceutical target in the intervention of this disease and further understanding of the NF-κB pathway will have an important implication on the development of novel and safe therapeutic strategies.

Download full-text PDF

Source
http://dx.doi.org/10.2174/187152811795564046DOI Listing

Publication Analysis

Top Keywords

type diabetes
24
nf-κb type
8
beta cells
8
autoreactive cells
8
nf-κb
6
diabetes
6
type
5
cells
5
diabetes type
4
diabetes autoimmune
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!